Safety Alerts & Recalls

What does this mean?

This recall for Avalide 300 mg/25 mg tablets from Bristol-Myers Squibb and Sanofi-Synthelabo was issued at a warehouse and pharmacy level only. The companies involved believe that any recalled product that may have been dispensed to patients does not pose a significant health risk. However, there is a possibility that these recalled tablets may be less effective at lowering blood pressure. If you take Avalide 300 mg/25 mg tablets and are concerned, you should speak to your doctor.

Bristol-Myers Squibb Co. is Recalling 60 Million Tablets of Avalide

On behalf of the Bristol-Myers Squibb and Sanofi-Synthelabo partnership, Bristol-Myers Squibb Co. is recalling 62 lots of Avalide 300 mg/25 mg tablets because of the possibility that one of the active ingredients in Avalide, irbesartan, may dissolve at a slower than optimal rate. Although a full review of post-marketing safety reports has not shown any evidence that the recalled tablets are less effective at lowering blood pressure, the company has issued the recall because they are unable to rule out that possibility.

Avalide contains the active ingredients irbesartan and hydrochlorothiazide. The recalled tablets contain 300 mg of irbesartan and 25 mg of hydrochlorothiazide. The recalled lot numbers were manufactured before November 2009.

For more information, please visit: more information here

Source: Manufacturer
Publication Date: 2010-10-04
Last Updated: 2010-10-04

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.